Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Edwards Lifesciences Corp (NYSE: EW) closed at $87.75 in the last session, up 0.91% from day before closing price of $86.96. In other words, the price has increased by $0.91 from its previous closing price. On the day, 2.66 million shares were traded. EW stock price reached its highest trading level at $87.93 during the session, while it also had its lowest trading level at $86.76.
Ratios:
We take a closer look at EW’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 82.08. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On February 02, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $94.
Evercore ISI Downgraded its Outperform to In-line on January 04, 2024, whereas the target price for the stock was revised from $80 to $77.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 09 ’24 when Lippis Daniel J. sold 857 shares for $92.34 per share. The transaction valued at 79,135 led to the insider holds 17,488 shares of the business.
Lemercier Jean-Luc M sold 14,400 shares of EW for $1,329,472 on Apr 08 ’24. The CVP, EMEACLA now owns 173,849 shares after completing the transaction at $92.32 per share. On Apr 08 ’24, another insider, BOBO DONALD E JR, who serves as the CVP,Strategy/Corp Development of the company, sold 12,500 shares for $92.33 each. As a result, the insider received 1,154,142 and left with 39,768 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 52819091456 and an Enterprise Value of 51408846848. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 38.13, and their Forward P/E ratio for the next fiscal year is 28.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.79 while its Price-to-Book (P/B) ratio in mrq is 7.93. Its current Enterprise Value per Revenue stands at 8.561 whereas that against EBITDA is 27.422.
Stock Price History:
Over the past 52 weeks, EW has reached a high of $96.12, while it has fallen to a 52-week low of $60.57. The 50-Day Moving Average of the stock is -2.45%, while the 200-Day Moving Average is calculated to be 11.45%.
Shares Statistics:
According to the various share statistics, EW traded on average about 4.01M shares per day over the past 3-months and 2891660 shares per day over the past 10 days. A total of 601.10M shares are outstanding, with a floating share count of 591.80M. Insiders hold about 1.58% of the company’s shares, while institutions hold 82.62% stake in the company. Shares short for EW as of 1711584000 were 10383747 with a Short Ratio of 2.59, compared to 1709164800 on 8441554. Therefore, it implies a Short% of Shares Outstanding of 10383747 and a Short% of Float of 1.7399999999999998.
Earnings Estimates
The market rating for Edwards Lifesciences Corp (EW) is a result of the insights provided by 25.0 analysts actively involved in the assessment.On average, analysts expect EPS of $0.64 for the current quarter, with a high estimate of $0.66 and a low estimate of $0.63, while EPS last year was $0.62. The consensus estimate for the next quarter is $0.7, with high estimates of $0.72 and low estimates of $0.67.
Analysts are recommending an EPS of between $2.8 and $2.65 for the fiscal current year, implying an average EPS of $2.75. EPS for the following year is $3.09, with 28.0 analysts recommending between $3.24 and $2.88.
Revenue Estimates
According to 24 analysts, the current quarter’s revenue is expected to be $1.57B. It ranges from a high estimate of $1.61B to a low estimate of $1.49B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.46BFor the next quarter, 24 analysts are estimating revenue of $1.64B. There is a high estimate of $1.68B for the next quarter, whereas the lowest estimate is $1.6B.
A total of 30 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.6B, while the lowest revenue estimate was $6.44B, resulting in an average revenue estimate of $6.52B. In the same quarter a year ago, actual revenue was $6BBased on 30 analysts’ estimates, the company’s revenue will be $7.15B in the next fiscal year. The high estimate is $7.33B and the low estimate is $6.95B.
